Market Drivers
Global Antibody-Drug Conjugate (ADC) Market Trends
April Stanley, MS MBA
Nice Insight
NI-8-26-MA-16Aug 26, 2026
Pathfinder
Site-Specific vs. Stochastic ADC Conjugation: Which Antibody–Drug Conjugate Strategy Is Better?
Nice Insight
PAO-26-PF-21Aug 21, 2026
Pathfinder
Cleavable vs. Non-Cleavable ADC Linkers: Which Antibody–Drug Conjugate Strategy Is Better?
Nice Insight
PAO-26-PF-20Aug 14, 2026
ATMP Supply Chain
Maintaining Resilient Supply Chains for Advanced Therapies
Pharma's Almanac
PAO-08-26-PA-09Aug 13, 2026
Asia Manufacturing
APAC Expands Specialized Manufacturing Capabilities Across High-Value Modalities
Pharma's Almanac
PAO-08-26-PA-02Aug 3, 2026
U.S. CDMO Capacity
More Than Capacity: What the Latest U.S. CDMO Expansion Wave Reveals About Specialized Manufacturing Demand
Pharma's Almanac
PAO-06-26-PA-18Jun 22, 2026
Biologics Patents
The Patent Landscape and its Implications: Biologics and ADCs
April Stanley, MS MBA
Nice Insight
NI-06-26-01Jun 1, 2026
ADCs
Re-Engineering ADCs for Autoimmune and Inflammatory Disease
David Alvaro, Ph.D.
Pharma's Almanac
PAO-05-26-PA-20May 21, 2026
Conjugation
Why ADC Conjugation Strategy Is Now a CMC Decision
David Alvaro, Ph.D.
Pharma's Almanac
PAO-05-26-PA-18May 20, 2026
ADC Platform
From mAbs to ADCs: Rethinking the Platform Manufacturing Model
David Alvaro, Ph.D.
Pharma's Almanac
PAO-05-26-PA-11May 11, 2026
ADC Linkers
Linker Chemistry as the Hidden Determinant of ADC Success
David Alvaro, Ph.D.
Pharma's Almanac
PAO-05-26-PA-10May 8, 2026
ADCs
Introduction to the Antibody Drug-Conjugate
April Stanley, MS MBA
Nice Insight
NI-03-26-01Mar 4, 2026